Colorado State University’s Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) has been awarded $2 million by the U.S. Department of Defense to aid in development and manufacturing of a vaccine to protect against infection by filoviruses, including the Ebola and Marburg viruses.

link